Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease - PPi-DIA
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Plasma pyrophosphate concentration [PPi]pl in children with CKD
研究概览
简要总结
The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.
详细描述
The study of pro- and anti-calcifying molecules in children with chronic kidney disease will be carried out using dosages made on serum in comparison with the dosage of these same molecules in control children matched according to age and sex. without chronic kidney disease. An evaluation of vascular function by clinical (auscultation, palpation) and ultrasound techniques (measurement of intima-media thickness and measurement of pulse wave velocity) will also be carried out in children with chronic kidney disease and compared to norms of children without chronic kidney disease. These evaluations aim to improve understanding of the pathophysiology of vascular calcification and thus open up therapeutic perspectives in these children.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 0 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All groups :
- •Minor patients (<18 years)
- •Patients of both sexes
- •Informed patients and parents who have signed the informed consent form
- •Patients affiliated to social security
- •Control group :
- •- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up
- •CKD groups :
- •Patients on dialysis for more than 3 months, regardless of technique
- •Kidney transplant patients
- •Patients with CKD, whatever the cause
排除标准
- •Progressive cancer or kidney disease
- •Treatments that may modify PPi concentration (e.g. bisphosphonates)
研究组 & 干预措施
CKD group
Patient with chronic kidney disease
干预措施: PPI and T50 dosing (Other)
Dialysis group
Dialysis patients (hemodialysis or peritoneal dialysis)
干预措施: PPI and T50 dosing (Other)
kidney transplant group
Kidney transplant patients
干预措施: PPI and T50 dosing (Other)
Control group
Control group of patients with normal renal function
干预措施: PPI and T50 dosing (Other)
结局指标
主要结局
Plasma pyrophosphate concentration [PPi]pl in children with CKD
时间窗: 18 months
Compare plasma pyrophosphate concentration \[PPi\]pl between children with CKD (dialysis group and non-dialysis, non-transplant group) and \[PPi\]pl of children with normal renal function. Plasma PPi concentration during fasting sampling; (μmol/L) by a proprietary assay developed at LP2M. We will match the 3 MRC groups with their respective control groups according to age, sex and pubertal stage.
次要结局
- Markers of vascular damage in CKD(18 months)
- Markers of phosphocalcic metabolism(18 months)
- Plasma pyrophosphate [PPi]pl concentration in children with renal transplantation(18 months)
- Urinary PPi concentration(18 months)